Y 20811

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341071

CAS#: 104363-98-6

Description: Y 20811 is a biochemical.

Chemical Structure

Y 20811
CAS# 104363-98-6

Theoretical Analysis

MedKoo Cat#: 341071
Name: Y 20811
CAS#: 104363-98-6
Chemical Formula: C20H19N2NaO3
Exact Mass: 358.1293
Molecular Weight: 358.3728
Elemental Analysis: C, 67.03; H, 5.34; N, 7.82; Na, 6.42; O, 13.39

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Y 20811; Y-20811; Y 20811

IUPAC/Chemical Name: Benzoic acid, 4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-, monosodium salt


InChi Code: InChI=1S/C20H20N2O3.Na/c1-12-4-5-16(22-7-6-21-11-22)10-17(12)19(23)18-13(2)8-15(20(24)25)9-14(18)3;/h4-11,19,23H,1-3H3,(H,24,25);/q;+1/p-1/t19-;/m1./s1

SMILES Code: [Na+].C(c1cc(c(c(c1)C)[C@@H](c1c(ccc(c1)n1ccnc1)C)O)C)(=O)[O-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 358.3728 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Sakai H, Suzuki T, Murota M, Takahashi Y, Takeguchi N. Nitric oxide-induced Cl- secretion in isolated rat colon is mediated by the release of thromboxane A2. J Physiol. 2002 Aug 15;543(Pt 1):261-71. PubMed PMID: 12181297; PubMed Central PMCID: PMC2290489.

2: Suzuki T, Sakai H, Takeguchi N. Thromboxane A(2)-mediated Cl(-) secretion induced by platelet-activating factor in isolated rat colon. Eur J Pharmacol. 2000 Jul 21;400(2-3):297-303. PubMed PMID: 10988347.

3: Sakai H, Sato T, Hamada N, Yasue M, Ikari A, Kakinoki B, Takeguchi N. Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon. J Physiol. 1997 Nov 15;505 ( Pt 1):133-44. PubMed PMID: 9409477; PubMed Central PMCID: PMC1160099.

4: Sumiyoshi A, Asada Y, Marutsuka K, Hayashi T, Kisanuki A, Tsuneyoshi A, Sato Y. Platelets and intimal thickening. Ann N Y Acad Sci. 1995 Jan 17;748:74-85; discussion 85. Review. PubMed PMID: 7695225.

5: Matsumoto Y, Noguchi Y, Inui J. [Effect of Y-20811, a thromboxane A2 synthetase inhibitor, on the arachidonic acid-induced response in the blood-superfused canine coronary artery]. Nihon Yakurigaku Zasshi. 1994 Feb;103(2):59-66. Japanese. PubMed PMID: 8112690.

6: Fujimura M, Mikashima H. Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits. Thromb Res. 1993 May 1;70(3):233-44. PubMed PMID: 8327988.

7: Sato N, Endo T, Kiuchi K, Hayakawa H. Effects of a thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occlusion and reperfusion in dogs. J Cardiovasc Pharmacol. 1993 Mar;21(3):353-61. PubMed PMID: 7681494.

8: Umemura K, Asai Y, Uematsu T, Nakashima M. Role of thromboxane A2 in a microcirculation disorder of the rat inner ear. Eur Arch Otorhinolaryngol. 1993;250(6):342-4. PubMed PMID: 8260145.

9: Fukuchi M, Uematsu T, Araki S, Nakashima M. Photochemically induced thrombosis of the rat coronary artery and functional evaluation of thrombus formation by occurrence of ventricular arrhythmias. Effects of acetylsalicylic acid and a thromboxane A2 synthetase inhibitor of thrombus formation. Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):550-4. PubMed PMID: 1470226.

10: Fujii T, Matsuzaki M, Oda T, Sakai H, Tanaka N, Yano M, Miura T, Kohno M, Katayama K, Kusukawa R. Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary stenosis. Jpn Circ J. 1992 Nov;56(11):1191-7. PubMed PMID: 1453545.

11: Takiguchi Y, Hirata Y, Wada K, Nakashima M. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb Res. 1992 Aug 15;67(4):435-45. PubMed PMID: 1412222.

12: Hayashi T, Asada Y, Kisanuki A, Sumiyoshi A. Effects of antithrombotic drug, Y-20811 on mural thrombus formation and intimal thickening following intimal injury. Thromb Res. 1992 Jul 1;67(1):81-94. PubMed PMID: 1440516.

13: Matsumoto Y, Ochi H, Aihara K, Inui J, Ikegami K. Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs. Eur J Pharmacol. 1992 Mar 24;213(2):167-70. PubMed PMID: 1521557.

14: Mikashima H, Ochi H, Muramoto Y, Hirotsu K, Arima N. Irreversible inhibition of thromboxane (TX) A2 synthesis by Y-20811, a selective TX synthetase inhibitor. Biochem Pharmacol. 1992 Jan 22;43(2):295-9. PubMed PMID: 1739418.

15: Kagoshima M, Tomomatsu N, Fukuda T, Mikashima H, Terasawa M. [Effects of Y-20811, a specific thromboxane A2 synthetase inhibitor, on chemical mediator-induced bronchoconstriction in guinea pigs]. Nihon Yakurigaku Zasshi. 1991 May;97(5):277-86. Japanese. PubMed PMID: 1908816.

16: Kagoshima M, Tomomatsu N, Aratani H, Terasawa M. Effect of Y-20811, a long-lasting thromboxane A2 synthetase inhibitor, on antigen-induced airway hyperresponsiveness in guinea pigs. Int Arch Allergy Appl Immunol. 1991;96(3):238-43. PubMed PMID: 1804796.

17: Iwata T, Mikashima H, Takamatsu R. Correlation between pharmacokinetics and pharmacologic effects of a new imidazole thromboxane synthetase inhibitor. J Pharm Sci. 1990 Apr;79(4):295-300. PubMed PMID: 2352139.

18: Mikashima H, Muramoto Y. Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. Thromb Res. 1990 Feb 15;57(4):499-505. PubMed PMID: 2326771.

19: Iwata T, Mikashima H, Isobe M, Takamatsu R, Yokobe T. [Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. II. Pharmacokinetics of intact drug and main metabolite in dog]. Yakugaku Zasshi. 1989 Nov;109(11):853-7. Japanese. PubMed PMID: 2614667.

20: Iwata T, Tsuruda M, Demizu K, Isobe M, Takamatsu R, Yokobe T. [Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. I. Isolation and structure elucidation of urinary metabolite in dog]. Yakugaku Zasshi. 1989 Sep;109(9):636-41. Japanese. PubMed PMID: 2607414.